{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T23:03:34Z","timestamp":1769641414865,"version":"3.49.0"},"reference-count":57,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":572,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2000,6]]},"abstract":"<jats:title>Abstract:<\/jats:title><jats:p>Availability of lipid formulations of amphotericin B has opened up the possibility of treating invasive fungal infections in immunocompromised patients with high doses of this antifungal agent. Evidence is emerging to suggest that lipid formulations may have heightened efficacy compared to conventional amphotericin B. The issue of optimal dosage has been a neglected area. This article reviews published data accrued from clinical, open\u2010label, salvage, and other studies, and finds little support that the use of high doses of lipid formulations are more efficacious than lower doses. The response rates for invasive fungal infection from most studies are predictably around 56%, irrespective of the lipid formulation and dose used. Animal models provide evidence that low doses of a lipid formulation are as successful in reducing fungal dissemination and in prolonging survival as higher doses, although concomitant tissue fungal eradication is not as effectively achieved by the lower doses (survival\u2010mycologic eradication dissociation). Kinetic studies performed in the clinically relevant setting of critically ill patients give further support to the use of low doses, since levels of liposomal amphotericin B at all dosages between 1 and 4 mg\/kg\/day are similar and above maximum inhibitory concentrations for commonly encountered fungi. There has only been one prospective randomised study designed with the primary end\u2010point of comparing two dosages of an amphotericin B lipid formulation on clinical response and survival. That European Organization for Research and Treatment of Cancer (EORTC) study concluded that liposomal amphotericin B given at 1 mg was as efficacious as 4 mg\/kg\/day in treating neutropenic patients with invasive pulmonary aspergillosis. There are a multitude of unanswered questions concerning dosing, and their answers are confounded by difficulties in performing clinical trials and the multiplicity of factors other than antifungal chemotherapy that influence outcome. Maximum tolerated dose studies using existing lipid formulations, or perhaps with the newer formulations such as pegylated immunoliposomal amphotericin B, could be performed to shed light on this difficult area.<\/jats:p>","DOI":"10.1034\/j.1399-3062.2000.020203.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T21:25:55Z","timestamp":1047504355000},"page":"51-61","source":"Crossref","is-referenced-by-count":25,"title":["Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections?"],"prefix":"10.1111","volume":"2","author":[{"given":"M.","family":"Ellis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"40","article-title":"The discovery and development of amphotericin B.","volume":"54","author":"Dutcher JD","year":"1968","journal-title":"Br J Dis Chest"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-10-199605150-00011"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.2.308"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/152.5.1037"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(68)90075-2"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1987.5.12.1985","article-title":"Favorable outcome of invasive aspergillosis in patients with acute leukemia.","volume":"5","author":"Burch PA","year":"1987","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_8_2","first-page":"1089","article-title":"Changes in the natural history of invasive pulmonary aspergillosis in neutropenic leukemic patients.","volume":"32","author":"Ruchlemer R","year":"1996","journal-title":"Isr J Med Sci"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.6.1147"},{"key":"e_1_2_6_10_2","first-page":"56","volume-title":"Aspergillus and Aspergillosis.","author":"Spreadbury CL","year":"1987"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.2.415"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/151.5.902"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-3505-2_19"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000238524"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000238138"},{"key":"e_1_2_6_16_2","first-page":"292","article-title":"Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug SCH28191.","volume":"129","author":"Graybill JR","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.29.4.602"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1128\/AAC.42.10.2569","article-title":"Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single cell level.","volume":"42","author":"Jahn B","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.4.755"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.1.172"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1128\/AAC.42.12.3103","article-title":"Efficacy of low dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients.","volume":"42","author":"Camp MJ","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(96)00075-6"},{"issue":"2","key":"e_1_2_6_23_2","first-page":"S93","article-title":"Liposomal and lipid based formulations of amphotericin B.","volume":"10","author":"Marie S","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199223040-00004"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/514672"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01575124"},{"key":"e_1_2_6_27_2","first-page":"635","article-title":"Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.","volume":"24","author":"White M","year":"1997","journal-title":"Clin Infect Dis"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700664"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700842"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701406"},{"key":"e_1_2_6_31_2","unstructured":"WingardJR WhiteMH AnaissieEJ et al.A randomised double blind safety study of Ambisome and Abelcet in febrile neutropenic patients.Abstract 015 In 9th Focus on Fungal Infections San Diego 1999."},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.2.315"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90663-7"},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1128\/AAC.42.9.2391","article-title":"Safety, tolerance and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (Ambisome) in neutropenic patients.","volume":"42","author":"Walsh TJ","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04825.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.155.10.1093"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1086\/516353"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.5.1145"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.2473063.x"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401004"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00944.x"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.6.1275"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/38.2.215"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.3.518"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.2.356"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.11.2660"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.suppl_B.73"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.5.1208"},{"key":"e_1_2_6_49_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1399-0012.1990.tb00047.x","article-title":"Liposomal amphotericin B (Ambisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation.","volume":"4","author":"Tollemar J","year":"1990","journal-title":"Clin Transplant"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1993.tb00748.x"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1086\/515033"},{"key":"e_1_2_6_52_2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/514704","article-title":"Lipid formulations of amphotericin B: clinical efficacy and toxicities.","volume":"27","author":"Wong\u2010Beringer A","year":"1998","journal-title":"Clin Infect Dis"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.1954"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.3.313"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1086\/516360"},{"key":"e_1_2_6_56_2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/iai.65.2.564-570.1997","article-title":"Th1 and Th2 cytokines in mice with invasive aspergillosis.","volume":"65","author":"Cenci E","year":"1997","journal-title":"Infection Immunity"},{"key":"e_1_2_6_57_2","unstructured":"AsciogluS.Definitions of fungal infections: definitions of the EORTC\u2010IFICG and NIAID\u2010MSG.Abstract #9 presented at Trends in Invasive Fungal Infections 5 Malta 1999."},{"key":"e_1_2_6_58_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/AAC.42.1.40","article-title":"Long circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice.","volume":"42","author":"Otsubo T","year":"1998","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-3062.2000.020203.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-3062.2000.020203.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1399-3062.2000.020203.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T10:25:40Z","timestamp":1733567140000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1399-3062.2000.020203.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,6]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,6]]}},"alternative-id":["10.1034\/j.1399-3062.2000.020203.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1399-3062.2000.020203.x","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,6]]}}}